Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

About this update from Immuneonco Biopharmaceuticals (shanghai) Inc Class H

[{"type":"image","alt":"Instil Bio","displaySize":"","headline":null,"caption":"Instil Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/38MAPe55bTDD07xl6tQzbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0bd42d0f6d237de2dc9b7724dfb8ae6b","width":300,"height":157}},"lazy":false},{"type":"text","content":"ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores","length":95,"tagName":"p"},{"type":"text","content":"Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+ NSCLC for PD-(L)1xVEGF bispecifics","length":133,"tagName":"p"},{"type":"text","content":"DALLAS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK) (“ImmuneOnco”) presented preliminary efficacy and safety data of ‘2510 (IMM2510/AXN-2510) as monotherapy in a Phase 1 study of patients in China with previously treated squamous non-small cell lung cancer (sq-NSCLC) at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Barcelona, Spain on September 9, 2025.","length":640,"tagName":"p"},{"type":"text","content":"ImmuneOnco reported that 23 patients with sq-NSCLC had been treated with monotherapy ‘2510 as of June 13, 2025. All patients had failed previous PD-(L)1 inhibitor plus platinum-doublet chemotherapy, and 6 patients had previously received VEGF-directed therapy. Patients were treated with ‘2510 at different dose levels (3, 6, 10, or 20 mg/kg Q2W), with the majority of patients treated at the 20 mg/kg Q2W dose level. In the 17 efficacy evaluable patients, the objective response rate (“ORR”) was 35.3%, with the majority of responses seen in patients with negative and low PD-L1 TPS scores. Most patients remain on treatment with the opportunity for additional tumor assessments, including multiple patients currently with stable disease. In general, ‘2510 was safe and well tolerated across the Phase 1 trial, with mostly...

More updates from Immuneonco Biopharmaceuticals (shanghai) Inc Class H